Exelixis (EXEL)
(Delayed Data from NSDQ)
$38.67 USD
-0.27 (-0.69%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $38.66 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Exelixis, Inc. has a market cap of $10.48B, which represents its share price of $38.94 multiplied by its outstanding shares number of 269.20M. As a large-cap company, EXEL's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
EXEL 38.67 -0.27(-0.69%)
Will EXEL be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for EXEL
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Here's Why Exelixis (EXEL) is a Strong Value Stock
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Other News for EXEL
Is EXEL preparing to trend higher? 20 Day Moving Average Support shows up after dropping 0.69%
Notable Two Hundred Day Moving Average Cross - EXEL
Is EXEL positioned for a breakdown? Stochastic Sell Signal shows up after declining 1.24%
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL)
Is EXEL gathering momentum? NR7 shows up after declining 1.61%